openPR Logo
Press release

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast To 2025

12-13-2016 09:32 AM CET | Health & Medicine

Press release from: Medical Research

Summary

Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems. MDD is characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and overeating or loss of appetite that can last from days to months, and alternates with episodes of wellness. Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental, and psychological factors that potentially increase the risk of MDD.

GlobalData epidemiologists forecast that the 12-month total prevalent cases of MDD in the 7MM will increase from 37,157,683 12-month total prevalent cases in 2015 to 38,142,749 12-month total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.27%. The US will have the highest number of 12-month total prevalent cases of MDD among the 7MM throughout the forecast period, while Japan will have the least number of 12-month total prevalent cases of MDD. As GlobalData epidemiologists used steady prevalence proportions of MDD over the forecast period, the growth in 12-month total prevalent cases in each market can be attributed to the change in population demographics.

GlobalData epidemiologists utilized country-specific and nationally representative peer-reviewed publications to forecast the 12-month total prevalent cases of MDD. The use of consistent methodology across the 7MM allows for a meaningful comparison of the forecast of 12-month total prevalent cases of MDD in these markets. Additionally, the 12-month total prevalent cases of MDD in each of the 7MM are segmented by severity, which can be of importance for predicting the prognosis and course of treatment. Lastly, the 12-month total prevalent cases of MDD in each of the 7MM are further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Download Sample copy of Report at http://www.marketresearchreports.biz/sample/sample/871711

Scope

- The Major Depressive Disorder (MDD) EpiCast Report provides an overview of the risk factors and global trends of MDD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of 12-month total prevalent cases of MDD segmented by age (18-19 years, in five-year increments from ages 20-84 years, and ending at ages 85 years and older), sex, and severity in these seven markets.
- The MDD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MDD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MDD therapeutics in each of the markets covered.
- Identify the percentage of MDD 12-month total prevalent cases by age, sex, and severity.

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EpiCast Report: Major Depressive Disorder - Epidemiology Forecast To 2025 here

News-ID: 394702 • Views:

More Releases from Medical Research

Competitor Analysis: Inhibitory And Stimulatory Immunomodulators In Immuno-Oncol …
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC). Purchase of this product includes a 6-month online access to

More Releases for MDD

Global Depression-MDD Drugs Market Analysis By Major Manufacturers and Competiti …
Global Depression-MDD Drugs Market: Driven factors and Restrictions factors The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones and current trends,
Depression-MDD Drugs Market Size, Share, Demand Forecast Report by 2030
Global Depression-MDD Drugs Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis Depression-MDD Drugs Market Overview The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Depression-MDD Drugs Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the
Major Depressive Disorder (MDD) - Drug Pipeline Landscape, 2022
Major Depressive Disorder (MDD) also known as clinical depression, is a severe mood disorder which causes persistent or extended periods of depressed or low mood, for more than 2 weeks and a loss of interest in activities thus affecting the mood and ability to function in daily life. To know more about Major Depressive Disorder (MDD), visit - https://www.globalinsightservices.com/reports/major-depressive-disorder-mdd-drug-pipeline-landscape-2022/ The most common causes of Major Depressive Disorder include genetics, trauma, isolation,
Major Depressive Disorder (MDD) Market In Depth Analysis 2021 To 2059Pfizer, Gla …
Complete study of the global Major Depressive Disorder (MDD) market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Major Depressive Disorder (MDD) industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the
U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2 …
This report is available at 10% Discount for Single user License, 20% Discount for Corporate User License till 30 September 2018. To avail discount please contact at +1-888-391-5441 / sales@marketreportsonline.com. Major Depressive Disorder Market (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. Place a
MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Forecast 2014 – …
The increasing prevalence of various psychological problems such as stress and sleeplessness is boosting the demand for MDD, anxiety, and panic disorder therapeutics. In its report, titled “MDD, Anxiety and Panic Disorder Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” Transparency Market Research (TMR) studies the various factors impacting the market’s trajectory. Download Exclusive Global Strategic Business Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928 Recent patent expiries did create a